0001664767-20-000001.txt : 20200821 0001664767-20-000001.hdr.sgml : 20200821 20200821134320 ACCESSION NUMBER: 0001664767-20-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200821 DATE AS OF CHANGE: 20200821 EFFECTIVENESS DATE: 20200821 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aequus Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001664767 IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-373814 FILM NUMBER: 201122772 BUSINESS ADDRESS: STREET 1: 2820-200 GRANVILLE STREET CITY: VANCOUVER STATE: A1 ZIP: BC V6C 1S4 BUSINESS PHONE: (604) 336-7906 MAIL ADDRESS: STREET 1: 2820-200 GRANVILLE STREET CITY: VANCOUVER STATE: A1 ZIP: BC V6C 1S4 D 1 primary_doc.xml X0708 D LIVE 0001664767 Aequus Pharmaceuticals Inc. 2820-200 GRANVILLE STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA V6C 1S4 (604) 336-7906 BRITISH COLUMBIA, CANADA None None Corporation true Doug Janzen 2820-200 Granville Street Vancoucer A1 BRITISH COLUMBIA, CANADA V6C 1S4 Executive Officer Director Ann Fehr 2820-200 Granville Street Vancouver A1 BRITISH COLUMBIA, CANADA V6C 1S4 Executive Officer Anne Stevens 2820-200 Granville Street Vancouver A1 BRITISH COLUMBIA, CANADA V6C 1S4 Executive Officer Director Stu Fowler 2820-200 Granville Street Vancouver A1 BRITISH COLUMBIA, CANADA V6C 1S4 Director Rodoula Plakogiannis 2820-200 Granville Street Vancouver A1 BRITISH COLUMBIA, CANADA V6C 1S4 Director Jason Flowerday 2820-200 Granville Street Vancouver A1 BRITISH COLUMBIA, CANADA V6C 1S4 Director Chris Clark 2820-200 Granville Street Vancouver A1 BRITISH COLUMBIA, CANADA V6C 1S4 Director Biotechnology $1,000,001 - $5,000,000 06b false 2020-08-06 true true true true true Each unit consists of one common share and one-half common share purchase warrant. Each whole warrant is exercisable for one common share at an exercise price of $0.12 per common share for a period of 36 months. false 0 Cormark Securities (USA) Limited 101000 None None Royal Bank Plaza, North Tower 200 Bay Street, Suite 1800 Toronto A6 ONTARIO, CANADA M5J 2J2 CA CALIFORNIA FL FLORIDA false 1899639 489016 1410623 The additional $1,410,623 may be received upon the exercise of share purchase warrants sold inside or outside the U.S. The U.S. dollar amounts are based on the Bank of Canada average rate of exchange reported on 8/6/2020, which was Cdn$1.3292=USD$1.00. false 2 24451 true 0 In connection to the offering, broker warrants were issued. 0 In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors. false Aequus Pharmaceuticals Inc. Ann Fehr Ann Fehr CFO 2020-08-20